CAP-100 / Catapult Therap - LARVOL DELTA

Targeting CCL19/21-CCR7 axis to overcome resistance to ALK inhibitors in ALK+ lymphoma (EACR 2025) - "CAP-100 boosts crizotinib activity in ALK+ ALCL PDX models by aiding the killing of DTPC in a subset of mice. The addition of CAP-100 to crizotinib markedly reduced the dissemination of lymphoma cells to the brain confirming our previous data that showed that genetic knock-out of CCR7 impaired lymphoma dissemination to the brain. Overall, these data show that the addition of CAP-100 to an ALK TKI could improve the cure rate and prevent lymphoma spread to critical sites like the brain."

CNS Disorders • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ALK • CCL19 • CCR7

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Catapult Therapeutics | Trial completion date: Apr 2025 ➔ Apr 2027 | Trial primary completion date: Jan 2025 ➔ Jan 2027

Monotherapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Catapult Therapeutics | Phase classification: P ➔ P1

Monotherapy • Phase classification • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P=N/A | N=25 | Recruiting | Sponsor: Catapult Therapeutics | Trial completion date: Sep 2023 ➔ Apr 2025 | Trial primary completion date: Sep 2023 ➔ Jan 2025

Monotherapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax. (PubMed, Hematol Oncol) - P=N/A | "The Bruton's tyrosine kinase inhibitor ibrutinib and the B-cell lymphoma 2 anti-apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). Our data indicate that venetoclax treatment did not significantly modify CCR7 expression pattern nor CAP-100 mechanisms of action. Together, these findings support CAP-100 as an adjuvant therapy to venetoclax that may introduce additional modes of action in CLL therapy."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2 • CCR7

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P=N/A; N=25; Recruiting; Sponsor: Catapult Therapeutics; Not yet recruiting ➔ Recruiting; Initiation date: Mar 2021 ➔ Sep 2021; Trial primary completion date: Mar 2023 ➔ Sep 2023

Enrollment open • Trial initiation date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. (PubMed, Cancer Immunol Immunother) - P=N/A | "Moreover, CLL cells are perfectly targetable by CAP-100 which led to a complete inhibition of CCR7-mediated migration and induced strong target cell killing through antibody-dependent cell-mediated cytotoxicity, irrespective of previous or contemporary ibrutinib administration. Together, these results validate the therapeutic utility of CAP-100 as a next-line single-agent therapy for CLL patients who failed to ibrutinib and confirm that CAP-100 and ibrutinib have complementary non-overlapping mechanisms of action, potentially allowing for combination therapy."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. (PubMed, MAbs) - P=N/A | "Our results validated CAP-100 as a novel therapeutic tool to prevent the access of CLL cells, and other neoplasia with nodal-dependence, into the LN niches, thus hitting a central hub in the pathogenesis of cancer. The first-in-human clinical trial (NCT04704323), which will evaluate this novel therapeutic approach in CLL patients, is pending."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7

Catapult Therapeutics receives FDA Clearance of Investigational New Drug (IND) Application for CAP-100, an innovative first-in-class humanized anti-CCR7 antibody (PRNewswire) - "Catapult Therapeutics...today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead product candidate CAP-100, an innovative first-in-class humanized anti-CCR7 antibody for treatment of hematological malignancies...Catapult Therapeutics is now poised to initiate a Phase 1 clinical trial in patients with relapsed or refractory CLL (chronic lymphocytic leukemia). Expected to begin in the second quarter of 2021..."

IND • New P1 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Oncology

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P; N=22; Not yet recruiting; Sponsor: Catapult Therapeutics

Clinical • Monotherapy • New trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology